Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab and Radiotherapy in Relapsed Refractory Multiple Myeloma
NCT03910439Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Oct 2019
- Primary completion
- Nov 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab in multiple myeloma (MM), sponsored by National Cancer Institute. Primary endpoint: Overall Response Rate at 11 months. Started Oct 2019; status: terminated.
02
Drugs
avelumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03910439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03910439.